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Summary
Clinical relevance: Measurement of markers of cartilage pathology in synovial fluid may provide clinical rheumatologists and osteoarthritis
(OA) researchers important information for early diagnosis of OA as well as a method for monitoring disease progression and response to
treatment. This study demonstrates the value of this approach in an established model of OA (cranial cruciate ligament rupture) at a point
distant enough from the original surgical manipulation so as to have little to no effect on the marker concentrations.
Objective: The objective of this study was to determine whether measurement of markers of cartilage collagen cleavage and proteoglycan
turnover in synovial fluid from a canine model could be used to detect cartilage changes following the onset of joint instability during the
development of OA.
Design: A model of joint instability that develops OA was created in 18 mature dogs using monopolar radiofrequency energy (MRFE). MRFE
was arthroscopically applied to one cranial cruciate ligament (CCL) while the contralateral CCL was sham treated. The treated CCLs
ruptured approximately 8 weeks (55±1.6 days) after MRFE treatment. Synovial fluid was collected at time zero prior to MRFE treatment, 4
weeks after MRFE treatment, and at 4, 8, and 16 weeks after CCL rupture. Synovial fluid concentrations of the neoepitope COL2-3/4C long
(type II collagen cleavage by collagenase) and epitopes 3B3(−) (proteoglycan aggrecan sulfation) and 846 (associated with aggrecan
synthesis) were analyzed.
Results: Compared to sham treated joints, the synovial fluid concentrations of COL2-3/4C long and 3B3(−) were significantly increased 2.2
fold and 2.9 fold, respectively, in joints with MRFE treated CCLs following CCL rupture. Concentrations of the 846 epitope in synovial fluid
showed a trend toward an increase, which was not significant, after CCL rupture.
Conclusions: Concentrations of the collagenase-cleaved type II collagen neoepitope and 3B3(−) epitope in synovial fluid were significantly
increased by 4 weeks and remained elevated for at least 16 weeks after CCL rupture. This suggests that in dogs the COL2-3/4C long
neoepitope and 3B3(−) epitope are sensitive markers for changes in joint cartilage turnover in joints that are developing OA. © 2002
OsteoArthritis Research Society International. Published by Elsevier Science Ltd. All rights reserved.
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Osteoarthritis (OA) is characterized by the progressive
degradation and erosion of articular cartilage in synovial
joints1. Many studies have been conducted over the past662two decades to investigate the pathogenesis and mechan-
isms of OA2–10. One proposed mechanism for the devel-
opment of OA is that disturbances in the balance between
synthesis and degradation of the extracellular cartilage
matrix are the initiating events11. Cartilage matrix consists
of two major macromolecules, type II collagen and the
proteoglycan aggrecan. Collagen fibrils provide tensile
strength to maintain tissue integrity, whereas aggrecan,
interwoven with the collagen fibrils, contributes to cartilage
matrix compressive stiffness12–14.
Damage to type II collagen and loss of aggrecan are
fundamental features of damage to articular cartilage in
OA. This is attributed to proteolytic enzymes secreted by
chondrocytes and synoviocytes. Three collagenases of
the matrix metalloproteinase (MMP) family—collagenase-
1 (MMP-1), collagenase-2 (MMP-8), and collagenase-3
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ANIMAL MODEL
Eighteen mature mixed-breed dogs were used with
the approval of the Institutional Animal Use and Care
Committee. All animals underwent bilateral stifle arthros-
copy during which MRFE (70°C, 25 W, ORA-50, Oratec
Interventions, Inc. Menlo Park, CA) was applied to one
randomly selected CCL while the contralateral stifle was
operated identically except that no energy was applied to
the CCL (sham treatment). Animal activity was unrestricted
after surgery. Rupture of the CCL in each treated limb was
detected by a sudden onset of non-weight-bearing lame-
ness, significant joint effusion, and a positive drawer sign in
the affected joint. Joint effusion was not detectable prior to
CCL rupture26. Complete dissolution of all treated CCLs
was confirmed at necropsy, and joints had osteoarthritic
changes characteristic of the canine CCL transection
model of OA21–23. Sham treatment joints were free of
pathologic changes and the CCL and caudal cruciate
ligament were intact. As part of an unrelated study, stifle
radiographs (caudocranial and lateromedial) were taken
pre-operatively and 4 weeks prior to rupture, and 4, 8, and
16 weeks following rupture26. Radiographs were evaluated
for standard signs of OA including the presence of osteo-
phytes, enthesiophytes, subchondral bone sclerosis, and,
following CCL rupture in one limb, cranial displacement of
the tibia relative to the femur. As mentioned previously, the
dogs were part of an unrelated study, which required
sacrifice at different time points, hence the number of
animals decreased over the duration of the study26.SAMPLE COLLECTION AND PREPARATION
Synovial fluid was aseptically collected (0.2–2.0 ml) from
each stifle. Specifically, 36 samples were collected from 18
dogs at time 0 (8 weeks prior to CCL rupture), 4 weeks prior
to rupture, and 4 and 8 weeks following rupture, and 24
samples were collected from 12 dogs at 16 weeks following
rupture. The samples were centrifuged at 10,000 rpm for
10 min, and the supernatant was aliquoted and stored at
−80°C until analysis. For COL2-3/4C long and 846 assays,
proteinase inhibitors were added to the samples which
included 1 mM EDTA, 1 mM PMSF (in isopropanol), 1 mM
iodoacetamide and 5 g/ml pepstatin A (in 100% ethanol) in
50 mM sodium acetate buffer, pH 5.0. Prior to assay enzy-
matic digestion of hyaluronic acid was performed at 37°
overnight with 0.4 TRU/ml of Streptomyces hyaluronidase
(Seikagaku Inc., Japan). For the 3B3(−) assay, undigested
samples of synovial fluid were assayed after making
appropriate dilutions.ELISAS
Immulon II microplates (Dynamics) were used for COL2-
3/4C long and 3B3(−) assays and duplicate samples were
used for each.(MMP-13)—are known to be responsible for the primary
cleavage of the triple helix of type II collagen15,16. Levels of
collagenase-mediated cleavage16 and denaturation17 of
type II collagen are increased in human osteoarthritic
cartilage. The collagenases cleave triple helical collagen at
a single site, resulting in a three-quarter and a one-quarter
fragment. A cartilage-specific type II collagen monoclonal
antibody has been developed to detect levels of the
carboxy terminal neoepitope of the three-quarter-piece
generated by collagenase at this primary cleavage site
(M. Ionescu and A. R. Poole, in preparation).
The proteoglycan (PG) aggrecan, another important
component of the cartilage matrix, consists of an extended
core protein to which chondroitin-sulfate and keratan sul-
fate glycosaminoglycans are attached9,14. Many studies
have been conducted of PG in OA2–5,14, and these have
shown that there are significant PG changes in the disease
process. A number of antibodies have been developed
over the last decade to detect epitopes reflective of PG
metabolism. Of particular interest are the PG chondroitin-
sulfate epitopes 3B3(−) and 846. Monoclonal antibody
3B3(−) recognizes PG bearing an epitope in native
chondroitin-sulfate glycosaminoglycan chains that possess
a saturated hexuronic acid residue adjacent to 6-sulfated
N-acetyl galactosamine at the non-reducing terminus of
the chondroitin-sulfate glycosaminoglycan3. It has been
reported that the 3B3(−) epitope is not present at signifi-
cant levels in normal cartilage, but increases in cartilage
and synovial fluid in human OA and in experimental animal
models of OA8,9. However, controversy exists about this
epitope. Plass and co-workers found that most of the
3B3(−) epitope from osteoarthritic cartilage was within
normal levels, with only 21% of the patients displaying
elevated 3B3(−) epitope reactivity18.
Monoclonal antibody 846 recognizes a chondroitin-
sulfate epitope on aggrecan that is maximally expressed in
fetal cartilage19. The 846 epitope is typically almost absent
from adult cartilage, but is usually increased in OA, with the
most marked increases in phase II of the disease in which
fibrillation is more extensive and cartilage becomes very
degenerative4,5. This epitope is present on the largest
molecules, and is a marker of elevated aggrecan synthesis.
Detection of elevations in the concentrations of the
above neoepitope and epitopes in synovial fluid is perhaps
the best way to identify subtle changes in cartilage turnover
in early stages of OA. Hazell8 and his group measured the
levels of synovial fluid 3B3(−) and 7D4 chondroitin-sulfate
epitopes, and 5D4 keratan sulfate epitope from injured
knees of patients with cruciate ligament and meniscal
damage. High levels of 3B3(−) and 7D4 were found in
most of the injured patients, while 5D4 epitope was
decreased. Ratcliffe et al.9 also reported that 3B3(−)
epitope in OA synovial fluid was elevated 33–35 fold.
Epitope 846 synovial fluid levels were high in OA patients
with the longest disease duration and greatest loss of
cartilage5, and increased in joint fluid following injury to that
joint20.
The objectives of this study were to determine synovial
fluid concentrations of COL2-3/4 long neoepitope and
3B3(−) and 846 epitopes following the creation of joint
instability in dogs and to monitor any subsequent changes
in their concentrations. We created an instability model by
applying monopolar radiofrequency energy (MRFE) arthro-
scopically to the cranial cruciate ligament (CCL) of the dog.
Following treatment, the CCL progressively deteriorated
over time until it naturally ruptured approximately 8 weeks
after MRFE treatment. Previous studies have shown thatrupture or surgical transectioning of the CCL or meniscec-
tomy in experimental animals favors the development
of OA21–25. This MRFE model avoids surgical sectioning
of the CCL. The concentrations of COL2-3/4C long
neoepitope and PG chondroitin-sulfate epitopes 3B3(−)
and 846 were measured in synovial fluid collected at
different time points before and after CCL rupture.
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Our previous data have shown that this monoclonal
antibody, which is specific for collagenase-cleaved type II
collagen, reacts with dog type II collagen cleaved by
collagenase 1 (MMP-1) (M. Ionescu and A. R. Poole,
unpublished). Peptide 287-KLH diluted in PBS, pH 7.2 was
used to coat Immulon II microplates at 5 ng/well (50 l/
well). The plates were incubated overnight at 4°C. After
washing three times with PBS containing 0.1% Tween 20
with a plate washer (ELP-40, BIO-TEK Instruments), the
plates were blocked with 100 l of 1% BSA in PBS, pH 7.2
for at least 30 min at room temperature, followed by wash-
ing three times as above. A standard curve was made with
peptide 287 ranging from 1000 ng–1.3 ng/ml diluted with
PBS buffer, pH 7.2, containing 1% BSA. Fifty l of synovial
fluid samples/standard was added to a round bottom poly-
propylene plate, then 50 l of COL2-3/4 long monoclonal
antibody diluted at 1:120,000 in PBS containing 1% BSA
and 0.1% Tween20, was added to the plate. After 1-h
incubation at 37°C, 50 l of the antigen-antibody mixture
was transferred to the coated Immulon II plate and incu-
bated for 30 min at 4°C. The plate was washed three times
as before. Secondary antibody, Goat anti-Mouse IgG, M, A
(H+L) Alkaline Phosphatase Conjugate (Zymed) diluted at
1:5,000 in PBS containing 1% BSA and 0.1% Tween20,
was added to the plate at 50 l per well. After 1-h incu-
bation at 37°C and washing the plate as above, 50 l of
substrate (ELISA Amplification System, GIBCO BRL) was
added to the plate and incubated for 15 min at room
temperature. Fifty l of amplifier (ELISA Amplification
System, GIBCO BRL) was then added for further 15-min
incubation. The reaction was stopped by adding 50 l of
0.3 M H2SO4. OD was obtained by reading the plate at
490 nm on an ELISA plate reader (EL 312e, Bio-Kinetics
Microplate Reader, BIO-TEK Instruments).3B3(−) epitope
A competitive ELISA method similar to that previously
described27 was used to determine the concentrations of
3B3(−) epitope in synovial fluid. Porcine aggrecan core
protein was kindly supplied by Dr Michael T. Bayliss, Royal
Veterinary College, London. Monoclonal antibody 3B3 was
purchased from Seikagaku, Japan.846 epitope
This was determined by radioimmunoassay, essentially
as previously described19. Bovine fetal PG was labeled
with 125I as the tracer, and iodination was completed by
using a standard procedure28. Bovine fetal aggrecan
was used as standard. All the samples were assayed in
triplicate.
Recoveries from each neoepitope and epitope were
determined by adding the standards to pooled samples.STATISTICS
Unpaired Student’s t-tests were used to compare
neoepitope or epitope concentrations between treated and
sham operated joints. ANOVA was used to evaluate the
effect of time and groups. When ANOVA revealed signifi-
cant differences over time, a post-hoc t-test (Scheffe’s
procedure) was performed to analyse these differences.Simple linear regression analysis was performed to corre-
late concentrations of markers and time points and to
correlate concentrations of 3B3(−) and COL2-3/4C long.
Differences were considered significant at P<0.05.ResultsCCL RUPTURE
Rupture of treated CCL’s was detected in 14 dogs by
sudden onset of non-weight bearing lameness, joint effu-
sion, and a positive drawer sign with joint manipulation. The
exact dates of rupture were not observed in four dogs. The
values from these animals were not used to calculate
the mean rupture date. Treated CCLs ruptured approxi-
mately 8 weeks after treatment (55±1.6; 48–66 days)
(Mean±S.E.M.; range).RADIOGRAPHIC CHANGES
The radiographic changes that occurred in joints with
MRFE treated CCLs and sham treated CCLs have been
reported previously26. Pre-operative and 4 week pre-
rupture radiographs did not have any significant changes.
Joints with sham treated CCLs did not have any significant
radiographic changes for the duration of the study. Four
weeks after CCL rupture, radiographs of stifles with treated
CCLs demonstrated significant joint effusion and some
degree of cranial displacement of the tibia relative to the
femur on the lateromedial view, both of which remained
present for the remainder of the study. The majority of the
joints with treated CCLs (14/18) had very early osteophyte
formation on the proximal trochlear ridges within the
femoropatellar joint. Radiographs performed on limbs with
treated CCLs 8 weeks post-rupture showed varying
degrees of osteoarthritic changes on the tibial intercondylar
eminences and femoral trochlear ridges. By 16 weeks after
CCL rupture, significant radiographic changes consisted
of osteophytosis of the tibial articular surface and the
trochlear ridges of the femur and slight subchondral bone
sclerosis of both the tibia and femur. Radiographic changes
in the 8 and 16 week post-rupture radiographs varied in
severity, but all joints had some degree of the changes
listed.COL2-3/4C LONG NEOEPITOPE
There were no differences between treated and sham
groups at 4 and 8 weeks prior to CCL rupture (Fig. 1).
However, after CCL rupture the neoepitope concentrations
were significantly increased: 1.7 fold at 4 weeks
(P<0.0001), 2.2 fold at 8 weeks (P<0.0001) and 1.7 fold at
16 weeks (P<0.02), compared with sham treated joints.
There were no differences over time between the sham
treated joints. Within the MRFE treated groups, COL2-3/4C
long neoepitope concentrations were significantly higher at
4 weeks and 8 weeks after rupture than at 4 and 8 weeks
prior to CCL rupture.3B3(−) EPITOPE
There were no differences between MRFE treated and
sham groups at 4 and 8 weeks prior to CCL rupture (Fig. 2).
3B3(−) epitope concentrations were significantly increased
Osteoarthritis and Cartilage Vol. 10, No. 8 665Fig. 1. Concentrations of COL2-3/4C long neoepitope in dog synovial fluid in CCL ruptured joint and sham-operated control.
Means±standard deviations are shown. *Significantly different (P<0.05).Fig. 2. Concentrations of PG chondroitin sulfate 3B3(−) epitope in dog synovial fluid in CCL ruptured joint and sham-operated control.
Means±standard deviations are shown. *Significantly different (P<0.05).in all the CCL ruptured groups compared to the sham
treated joints. They were 1.7 fold higher at 4 weeks
(P<0.0001), 2.9 fold higher at 8 weeks (P<0.0001) and 2.4
fold higher at 16 weeks (P<0.0001) following CCL rupture
compared to the sham operated joints. Within the MRFE
treated group, 3B3(−) epitope concentrations at 4, 8, and
16 weeks following rupture were higher than those 8 weeks
before rupture. Moreover, concentrations at 4 and 8 weeksfollowing rupture were higher than those at 4 weeks prior
to rupture. Significant differences among some time points
within the sham treated group were also identified. Concen-
trations at 4 weeks prior to CCL rupture were higher than
8 and 16 weeks after CCL rupture. An increase in 3B3(−)
concentrations was correlated significantly with increasing
COL2-3/4C long concentrations (P<0.0001, r 2=0.23)
(Fig. 3).
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The concentrations of 846 epitope showed a trend for
an increase, which was not significant, in the MRFE
treated group, starting at 4 weeks after CCL rupture and
remained higher until 16 weeks after CCL rupture (Fig. 4).
Regression analysis showed a weak but significant corre-
lation (r2=0.35, P<0.01) between 846 epitope concen-
tration and duration of CCL rupture. The concentrations
initially decreased and then increased at later time points.
There were no differences within the sham operated group
over time.Average recovery rate for COL2-3/4C long assay was
112±4.0%; 99±3.0% for 3B3(−) and 91.5±3.5% for 846
assays.Fig. 3. Linear regression of synovial fluid COL2-3/4C long neoepitope to synovial fluid 3B3(−) epitope concentrations.Fig. 4. Concentrations of PG chondroitin sulfate 846 epitope in dog synovial fluid in CCL ruptured joint and sham-operated control.
Means±standard deviations are shown.Discussion
This study examined the potential for biochemical
markers to detect OA in a novel model of canine CCL
disruption. The use of MRFE to cause the degeneration
and rupture of the canine CCL approximately 8 weeks after
surgery allowed resolution of many of the changes caused
Osteoarthritis and Cartilage Vol. 10, No. 8 667by surgical manipulation of the joints. Hence, concen-
trations of COL2-3/4C long, 3B3(−), and 846 could be
evaluated as they changed relative to the changes in joint
health as a result of joint instability. The goal of the study
was to evaluate the markers for their potential to detect the
earliest signs of articular surface disruption even before
changes were evident in all joints radiographically. Using
this novel model of canine CCL disruption, there was
increased degradation of type II collagen and changes
in aggrecan turnover early following induction of joint in-
stability. The results suggest that in the dog, the COL2-
3/4C long neoepitope and the 3B3(−) epitope are useful
markers for the detection of early changes in cartilage
metabolism during the development of OA.
Biochemical markers may be useful for early diagnosis,
determining contributing factors, and monitoring disease
progression and response to therapy during the develop-
ment of OA. Cartilage degradation and synthesis can now
be detected in vitro by using antibodies29. The collagenase
generated type II collagen cleavage can be detected and
measured16. Synthesis of type II procollagen can be
detected and measured by measuring the C-propeptide of
the molecule30. Agreccan epitopes of keratan sulfate31,
3B3(−)32 and 84620 can also be detected with antibodies.
In this study, we examined type II collagen neoepitope
COL2-3/4C long, and PG epitopes 3B3(−) and 846 as
biochemical markers of cartilage turnover. The two major
macromolecules of articular cartilage extracellular matrix
are type II collagen and the proteoglycan aggrecan. The
neoepitope COL2-3/4C long generated by collagenase
cleavage of type II collagen is a logical choice since
collagenase activity is considered to play a significant role
in the cleavage of type II collagen and it is elevated in
OA16. However, the chondroitin sulfate epitopes 3B3(−)
and 846 are present in developing tissues, disappear in the
adult and reappear in osteoarthritic cartilage2,14. The latter
changes might represent an attempt to repair the altered
microenvironment2,14. We measured the concentrations of
these three markers in the synovial fluid of dogs with joint
instability that would favor development of OA to determine
changes in their levels at different time points in the disease
progression.
Creation of joint instability by transection of the CCL and
meniscectomy has been clearly shown to result in OA in the
dog22–25. We applied MRFE arthroscopically to one CCL in
each dog, without performing an arthrotomy or transecting
ligaments, thus resulting in an accelerated but naturally
occurring CCL rupture with minimal surgical trauma. Syno-
vial fluid concentrations of COL2-3/4C long neoepitope and
3B3(−) epitope were unchanged at 4 weeks after MRFE
treatment (4 weeks before rupture). Significant increases in
the COL2-3/4C long neoepitope and 3B3(−) epitope con-
centrations were observed at 4 weeks after CCL rupture
and the concentrations remained significantly higher than
the sham operated controls for at least 16 weeks following
rupture.
The elevation of COL2-3/4C long neoepitope in the
synovial fluid from the current study reflects the colla-
genase activity that leads to excessive degradation of
collagen (A.R. Poole, L. Dahlberg, M. Ionescu and R.C.
Billinghurst unpublished). Degradation of cartilage matrix
involves the extracellular cleavage of matrix molecules.
Collagenases MMP-1, MMP-8, and MMP-13 are the
enzymes currently known to cleave the cartilage matrix
collagen16. These enzymes mainly originate in synovial
cells and chondrocytes33. In the early stages of OA, carti-
lage attempts to repair the tissue damage. Chondrocytesmay proliferate and secrete more degradative enzymes,
modulated by certain cytokines, leading to excessive deg-
radation of cartilage matrix molecules. We did not measure
the levels of collagenases in this study. However, increased
denaturation of the triple helix of type II collagen, in which
collagenases are involved, has been reported to occur in
human articular cartilage during OA development7,17.
Another study has shown that the immunoreactivities for
collagenase-1 and collagenase-3 were increased dramati-
cally in the early phases of experimentally induced canine
OA34. Similarly, our study showed significant elevations
in the synovial fluid concentrations of COL2-3/4C long
neoepitope 4, 8, and 16 weeks after CCL rupture compared
to controls. This reveals an abnormal degradation of type II
collagen in the early phases of canine OA.
The 3B3(−) changes we noted are similar to the findings
of a previous study using an acute canine cranial cruciate
ligament transection model in which there were significant
elevations of 3B3(−) levels in synovial fluid from CCL
transected joints, compared to the controls33. 3B3(−)
epitope levels in synovial fluid are also elevated following
post-traumatic OA caused by surgical damage to the
menisci in dogs. The levels of 3B3(−) epitope peaked at 4
weeks after meniscectomy, and remained above the base-
line at 12 weeks25. This indicates changes in aggrecan
turnover in early stages of OA indicative of cartilage degra-
dation. Interestingly, concentrations of 3B3(−) epitope and
COL2-3/4C long neoepitope both peaked at 8 weeks after
CCL rupture (2.9 fold for 3B3(−), and 2.2 fold for COL2-3/
4C). In addition, there was a significant positive correlation
between the 3B3(−) epitope and COL2-3/4C long
neoepitope (P<0.0001, r 2=0.23). This may best be
explained as increased damage to cartilage type II collagen
that is combined with cartilage aggrecan turnover. In such
cases, chondrocytes exhibit increased proliferation and
there is an increase in matrix synthesis36. Degradation and
synthesis of type II collagen and aggrecan occur together
with the development of OA. The concentrations of 3B3(−)
epitope from the sham treated group showed a slight
increase after MRFE treatment of the contralateral CCL.
The reasons for this remain to be established.
The concentration of the 836 epitope showed an increas-
ing trend at 4 weeks after CCL rupture in the MRFE treated
group, but it was not statistically different from sham
operated controls. This epitope is increased in OA carti-
lage4 and in human knee joints following injury20. It is at its
highest in human knee OA where synovial fluid content is
markedly increased5,20. In rabbit OA induced by cranial
cruciate ligament transection and medial meniscectomy,
846 epitope is also elevated at 12 weeks (A. R. Poole, L.
Killar et al., unpublished). Thus, this difference may be
peculiar to the dog or the model. Further study is required
to demonstrate whether an elevation of 846 epitope in
aggrecan extracted from fetal canine cartilage is present
when compared with aggrecan from normal adult canine
cartilage.
We are presenting the information in this paper as a
potential technique by which joint disease can be assessed
with greater sensitivity and specificity than standard imag-
ing modalities. Our purpose was to establish methods by
which disease progression and therapeutic effects can be
assessed both clinically and for research purposes. With
this thought in mind, we feel that the neoepitope/epitope
concentrations in the joint fluid are more significant than
their absolute concentrations. This is so because we are
assuming that though the disease of OA is progressive,
changes in the concentrations at any given time are so
668 Q. Chu et al.: Elevation of a collagenase generated type II collagenslight that they may be considered to be at steady-state
concentrations.
In summary, using a novel model of canine CCL disrup-
tion, COL2-3/4C long and 3B3(−) were found to be useful
indicators of early changes in cartilage metabolism which
predicted the onset of radiographic changes characteristic
of OA. These markers may prove very useful in research
studies seeking to prevent or alleviate the manifestations of
OA prior to irreversible changes. Further studies are
required to determine potential clinical applications of the
markers, but it is possible that that they may be used in
cases where joint pain occurs before radiographic evidence
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